Ultimovacs ASA (Norway) Price Prediction
| ULTI Stock | NOK 2.07 0.02 0.98% |
Oversold Vs Overbought
41
Oversold | Overbought |
Using Ultimovacs ASA hype-based prediction, you can estimate the value of Ultimovacs ASA from the perspective of Ultimovacs ASA response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Ultimovacs ASA to buy its stock at a price that has no basis in reality. In that case, they are not buying Ultimovacs because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Ultimovacs ASA after-hype prediction price | NOK 2.07 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Ultimovacs |
Ultimovacs ASA After-Hype Price Prediction Density Analysis
As far as predicting the price of Ultimovacs ASA at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Ultimovacs ASA or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Ultimovacs ASA, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Ultimovacs ASA Estimiated After-Hype Price Volatility
In the context of predicting Ultimovacs ASA's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Ultimovacs ASA's historical news coverage. Ultimovacs ASA's after-hype downside and upside margins for the prediction period are 0.10 and 8.73, respectively. We have considered Ultimovacs ASA's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Ultimovacs ASA is dangerous at this time. Analysis and calculation of next after-hype price of Ultimovacs ASA is based on 3 months time horizon.
Ultimovacs ASA Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Ultimovacs ASA is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Ultimovacs ASA backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Ultimovacs ASA, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.21 | 6.66 | 0.00 | 0.00 | 0 Events / Month | 0 Events / Month | Any time |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
2.07 | 2.07 | 0.00 |
|
Ultimovacs ASA Hype Timeline
Ultimovacs ASA is at this time traded for 2.07on Oslo Stock Exchange of Norway. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Ultimovacs is expected not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is expected to be very small, whereas the daily expected return is at this time at -0.21%. %. The volatility of related hype on Ultimovacs ASA is about 0.0%, with the expected price after the next announcement by competition of 2.07. About 48.0% of the company outstanding shares are owned by insiders. The company recorded a loss per share of 5.09. Ultimovacs ASA had not issued any dividends in recent years. Assuming the 90 days trading horizon the next expected press release will be any time. Check out Ultimovacs ASA Basic Forecasting Models to cross-verify your projections.Ultimovacs ASA Related Hype Analysis
Having access to credible news sources related to Ultimovacs ASA's direct competition is more important than ever and may enhance your ability to predict Ultimovacs ASA's future price movements. Getting to know how Ultimovacs ASA's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Ultimovacs ASA may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| BGBIO | Bergenbio ASA | 0.00 | 0 per month | 4.59 | 0.04 | 15.00 | (8.54) | 51.26 | |
| NYKD | Nykode Therapeutics ASA | 0.00 | 0 per month | 0.00 | (0.18) | 8.71 | (7.10) | 53.57 | |
| PCIB | PCI Biotech Holding | 0.00 | 0 per month | 3.87 | 0.03 | 7.14 | (5.96) | 17.11 |
Ultimovacs ASA Additional Predictive Modules
Most predictive techniques to examine Ultimovacs price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Ultimovacs using various technical indicators. When you analyze Ultimovacs charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Ultimovacs ASA Predictive Indicators
The successful prediction of Ultimovacs ASA stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Ultimovacs ASA, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Ultimovacs ASA based on analysis of Ultimovacs ASA hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Ultimovacs ASA's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Ultimovacs ASA's related companies.
Story Coverage note for Ultimovacs ASA
The number of cover stories for Ultimovacs ASA depends on current market conditions and Ultimovacs ASA's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Ultimovacs ASA is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Ultimovacs ASA's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Other Macroaxis Stories
Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios
Story Categories
Currently Trending Categories
Ultimovacs ASA Short Properties
Ultimovacs ASA's future price predictability will typically decrease when Ultimovacs ASA's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Ultimovacs ASA often depends not only on the future outlook of the potential Ultimovacs ASA's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Ultimovacs ASA's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 34.2 M | |
| Cash And Short Term Investments | 574.2 M |
Other Information on Investing in Ultimovacs Stock
Ultimovacs ASA financial ratios help investors to determine whether Ultimovacs Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ultimovacs with respect to the benefits of owning Ultimovacs ASA security.